Quantcast

Latest biopharmaceutical Stories

2014-07-22 08:32:59

TEL AVIV, Israel, July 22, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that the U.S. Food and Drug Administration, or the FDA, cleared Galmed's Investigational New Drug, or IND, application. Such clearance will permit Galmed to conduct clinical trials of...

2014-07-21 08:27:28

LONDON, July 21, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Editionhttps://www.reportbuyer.com/product/2076279/The-World-Market-for-Biosimlars-EPO-G-CSF-HGH-Insulin-Interferon-Alpha-Monoclonal-Antibodies-Other-4th-Edition.html This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs,...

2014-07-18 16:23:22

TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2014 financial and operating results on Tuesday, August 5, 2014, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the...

2014-07-15 12:29:09

BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis. According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property. We regularly work with biopharmaceuticals and...

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....

2014-07-14 12:26:49

CHENGDU,China, July 14, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided updates regarding the Company's Qionglai Facility (QLF). QLF, after the completion of its construction followed by the equipment installation, has conducted a series of procedures and tests that...

2014-07-10 12:30:51

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ -- On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD [http://biocad.ru/en ]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science ]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune...

2014-07-09 08:28:06

REDWOOD CITY, Calif., July 9, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), announced today the appointment of V. Bryan Lawlis, Jr., Ph.D., former President and CEO of Itero Biopharmaceuticals, to its Board of Directors. "It is a privilege to join this talented Board of Directors, and I am excited about the opportunity to work with the Board and management to make Coherus the leader in the emerging business of biosimilars," Dr. Lawlis stated. "I look forward to working...

2014-07-02 23:06:03

Spread across 210 pages, cell culture market research report by equipment, reagent and applications forecasts the cell culture industry to grow at a CAGR of 10.71% between 2013 and 2018, to reach $24,574 million in 2018. The key drivers for this market are rapid increase in the demand for biopharmaceuticals and increased adoption of single-use technology. Dallas, TX (PRWEB) July 02, 2014 Cell Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent (Media, Sera, Growth...

2014-07-02 16:25:04

SEATTLE, July 2, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, today announced that it has entered in to a Commercial Supply Agreement with Portola Pharmaceuticals, a biopharmaceutical company for the development of andexanet alfa, a potential first-in class Factor Xa inhibitor antidote in Phase 3 ANNEXA(TM) (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. Andexanet alfa is...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.